Annovis stock jumps on data for Parkinson’s drug (NYSE:ANVS)
2024-07-02
Hailshadow/iStock via Getty Images Shares of Annovis Bio (NYSE:ANVS) more than doubled in value on Tuesday after the company said its lead asset, buntanetap, was found to be safe and effective in improving the physical and cognitive functions of patients with early Parkinson’s disease. Updating data from its Phase 3Continue Reading